ArticleCell biomaterials2026
Breaking barriers in gynecologic malignancies with adoptive cell transfers and nanomedicine.
Article in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gynecologic cancers remain challenging malignancies to treat, with little improvement in survival outcomes since the introduction of platinum-based chemotherapy in the 1970s. These tumors are characterized by dense extracellular matrices, heterogeneous immune infiltrates, and immunosuppressive microenvironments that limit the success of standard therapies. Adoptive cell transfers (ACTs) have shown promise in overcoming these barriers, yet their development in gynecologic oncology lags behind that of other cancers. This perspective outlines factors contributing to this gap, current ACT approaches, including tumor-infiltrating lymphocytes, T-cell receptor-engineered T-cells, and chimeric antigen receptor cells, and evaluates their relevance in ovarian, endometrial, and cervical cancers. We highlight emergent strategies that integrate immune cell trafficking with biomaterials designed to improve localization, retention, and controlled drug release within tumors. We consider the relative advantages and limitations of each approach and offer practical considerations for developing these technologies to reshape clinical treatment paradigms for gynecologic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.